Pfizer (PFE) and Novartis (NVS) are pairing up on new clinical trials of combination therapies to treat the fatty liver disease known as NASH.
The collaboration between the pharma giants announced Monday won’t yield significant clinical results for quite some time, but scientists working at both companies say attacking NASH with two or more drugs that act in the liver differently will ultimately bring the most benefit to patients.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
This is very informative and useful. Needs regular information. Please send all latest news of Pharma industry.